Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"Initial interim data from the Phase 1/2 study with STEM's HuCNS-SC cells in geographic atrophy age-related macular degeneration were extraordinarily encouraging." (7/31/14) StemCells Inc. - The Life Sciences Report Interview with Christopher James More >
Brad J. Spellberg, M.D., is professor of medicine at the David Geffen School of Medicine at UCLA and the Harbor-UCLA Medical Center. He is also the associate medical director for inpatient services, and an associate program director for the Internal Medicine Residency Training Program at Harbor-UCLA Medical Center. He received his bachelor's degree in molecular cell biology-immunology in 1994 from the University of California, Berkeley. He then attended medical school at the Geffen School of Medicine at UCLA, where he received numerous academic honors, including serving as the UCLA AOA Chapter co-president and winning the prestigious Stafford Warren award for top academic performance in his graduating class. Spellberg completed his residency in internal medicine and subspecialty fellowship in infectious diseases at Harbor-UCLA Medical Center, where he received the department of medicine's Subspecialty Fellow of the Year award. He serves on the scientific advisory board for Synthetic Biologics Inc.
Deadly Bacteria Are a Global Crisis: Brad Spellberg (6/20/13) Antibiotic-resistant bacteria, like the proverbial time bomb, are poised to wreak infectious havoc on a worldwide scale. Brad Spellberg, associate professor of medicine at the Los Angeles Biomedical Research Institute and the Harbor-UCLA Medical Center, is committed to defusing the bomb with the development of new antibiotics and creative platforms. He believes investigators must look at alternative ways to deal with bad bugs, perhaps by neutralizing their toxic effects rather than killing them. In this interview with The Life Sciences Report, Spellberg explores this critical issue and names four companies with novel technologies that address this looming global crisis.
"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino More >